INTRODUCTION
Quantitative differences in transplant rates of hematopoietic stem cell transplantation (HSCT) have been well described in the recent past: more patients are transplanted in countries with a higher national income. HSCT requires a specific infrastructure, depends on a network of specialists and remains associated with significant morbidity and mortality; it is a prime example of costly specialized medicine. Broader use of HSCT has therefore long been limited to high income countries (1, 2) . This has changed over the last decade, for several reasons.
Transplantation of autologous or allogeneic bone marrow, peripheral blood or cord blood stem cells has become treatment of choice for many patients with defined severe congenital or acquired disorders of the hematopoietic system. Unrelated donor registries have expanded to more than 20 million HLA-typed (Human Leukocyte Antigen) volunteer donors worldwide and increased the likelihood to find a suitable matched donor. Results have improved, including those for elderly patients and for those with co morbidities. As a consequence, novel indications are being explored and transplant numbers have increased worldwide (3) (4) (5) (6) (7) (8) (9) .
Furthermore, the World Health Organization (WHO) has recognized transplantation as an important global task. Transplantation of cells, tissues and organs has extended the lifespan of hundreds of thousands of patients worldwide and enhanced their quality of life; it has become standard of care for many patients with single organ failure and should no longer be restricted to affluent countries or individuals. The guiding principles of the WHO declare regulation of transplantation on a national level as a governmental responsibility. Regulation includes harmonized data collection on use and outcome as an essential tool to improve results and to achieve efficient and cost effective use of resources (10, 11) . Information on use and trends is therefore a prime prerequisite for any health care agency. The Worldwide Network for Blood and Marrow Transplantation (WBMT), an umbrella organization of HSCT and a non-governmental organization recognized by WHO has taken up the task of facilitating HSCT. It previously identified availability of resources, governmental support and access of patients to the therapy as key factors associated with quantitative differences in transplant rates (12) . It presents now an in-depth assessment of factors associated with qualitative differences in use and trends on a global level.
METHODS

Study design
This retrospective survey followed the principles of the WBMT through data collection by its network of international or regional member organizations (12) . Main outcome measures were the assessment of transplant rates by indication and donor type for each country, the changes (Table 1) . Data were reported via the mandatory worldwide compatible reporting system of initial transplant data (ABMTRR, CBMTG, and CIBMTR) or by a separate survey data form (APBMT, EBMT, EMBMT, and SBTMO) (9, (13) (14) (15) (16) .
Data were pooled, validated through confirmation by the reporting team, which received a computer printout of the entered data, by selective comparison with MED-A data sets in the EBMT ProMISE data system or by crosschecking with National Registries. Double reporting was excluded. Onsite visits of selected teams are part of the quality control program within CIBMTR and EBMT teams.
Definitions
Transplant rates
Transplant rates were computed as the number of patients treated with a first HSCT per 10 million inhabitants (2) . Patients with a re-transplant or a second or third HSCT were not included.
Population data and data on Gross National Income/capita (GNI/cap), Health Care Expenditures/cap, Governmental Health Care Expenditures, and World Bank Category (by GNI/cap) were obtained from the World Bank (www.worldbank.org) and from the International Monetary Fund (www.imf.org).
World Health Organization regional offices areas
The allocation of individual countries to a region followed the WHO regional offices classification (www.who.int/about/regions/en/) and the previously reported restriction to four regions (11): 1) the Americas; 2) Asia; 3) Eastern-Mediterranean and Africa; and 4) Europe (Figure 1 ).
Statistical analysis
The association of macroeconomic factors with HSCT rates and the changes from 2006 to 2008 were estimated by single and multiple linear regression analyses using the least squares method. The significance of relationships was measured using τ statistics; a level of 5% was considered significant. The goodness of fit was calculated using the coefficient of Table 1 ).
Information on stem cell source was available on a total of 142,822 patients. Peripheral blood was used predominantly in related and unrelated HSCT (64%) and in autologous HSCT (98%).
Bone marrow remained an important source for allogeneic HSCT (26%), specifically for non malignant disorders (56%); its use was minimal for autologous HSCT (2%). Allogeneic HSCT (in patients with information on stem cell source available) were performed from family donors in 51% (43% matched, 7% mismatched/haplo, 0.5% twins and 0.43% cord blood) and from unrelated donors in 49%. Of the 49% unrelated HSCT, 54% were obtained from peripheral blood, 27% from bone marrow and 19% from cord blood.
The highest number of HSCT was reported from Europe (51% of which 39% allogeneic HSCT)
followed by the Americas (29%; 46% allogeneic HSCT), Asia (18%; 60% allogeneic HSCT) and Eastern Mediterranean/Africa (3%; 63% allogeneic HSCT) as shown in Table 1 
Transplant rates
Over the three years period the average absolute number of HSCT in the participating countries ranged from 1 (Philippines) to 11,228 HSCT (USA; Figure 1 ). Transplant rate ranged from 0.1 to 732 per 10 million inhabitants (median 119) for total HSCT, from 0 to 397 (median 49) for allogeneic and from 0 to 412 (median 81) for autologous HSCT. There were no autologous or allogeneic transplants in countries with less than 300,000 inhabitants or with a GNI/cap below $US 690; there were no unrelated donor transplants in countries with a GNI/cap below $US 850. Relative increase was greater for related and unrelated allogeneic (+17%) than for autologous HSCT (+ 5%; see Figure 4A ). The highest increase in absolute and relative numbers was observed in the Asia/Western Pacific region (see Figure 4B ; +39%) for allogeneic (+50%) and autologous (+22%) HSCT, followed by Europe (+6%) for allogeneic (+10%) and autologous (+3%) HSCT, Americas (4%) for allogeneic (+9%) and autologous (+1%) HSCT, and EMRO/Africa (+19) for allogeneic (+11%) and autologous (+34%) HSCT. The relative increase in HSCT numbers was higher in low income countries ( Figure 4C ) but not in absolute numbers and in transplant rates (see below). The increase in HSCT numbers was predominantly accounted for by unrelated donor HSCT for patients with leukemia in America and Europe, by family donor HSCT for patients with non malignant disorders in Asia and EMRO/Africa.
Numbers of autologous HSCT increased for for lymphoproliferative disorders (+8%) and decreased for leukemia (-15%) and solid tumors (-2%) as shown in Figure 4D . Numbers of allogeneic HSCT increased for leukemia (+20%) and non malignant disorders (+26%; Figure   4E ) with divergent trends for myelodysplasia (+26%), acute myeloid leukemia (+23%), acute lymphoblastic (+27%) leukemias and chronic lymphocytic (+24.6%) leukemia than for chronic myeloid leukemia (-17%). The numbers of allogeneic HSCT increased for bone marrow failure syndromes (+21%) and other non-malignant disorders (+27%). Changes in use of stem cell source are shown in Figure 4F with the highest relative but not absolute increase in cord blood HSCT. The relatively higher increase in transplant numbers in countries with lower income (R² = 11%) did not translate into a higher increase in transplant rates. In contrast transplant rates were weakly but positively associated with lnGNI/cap (R² = 3%) (Figure 3d ). Linear trend analysis confirms this with a positive and increasing linear trend (p=0.02, total HSCT) for the absolute number of HSCT in high income countries but none for the middle (p=0.57) and low (p=0. 35) income countries. The trend was most clearly underpinned for unrelated donor HSCT for acute leukemia in high income countries (p=0.004). There was no association of increase or decrease in transplant rates with change in lnGNI/cap over time (R² = 1%). indications or chronic leukemia. The previously described differences between the WHO regional offices areas (11) might therefore rather reflect the differences in resources than in opinions. It is comforting to observe the continued increase in transplant numbers in low income countries; it remains of concern that transplant rates increased to a greater extent in high income compared to middle or low income countries: the gap remains widening.
Transplant rates were associated with GNI/cap for all indications and all donor types but with vast differences in explanatory content and impact. How can these findings be interpreted? A high explanatory content with a strong impact can be considered as a situation with increasing demand without saturation: more patients with acute leukemia will be transplanted in the coming years if the necessary resources, money and donors can be made available. A low explanatory content with a weak impact indicates a different situation. Transplant rates are no longer driven by a higher national income alone. Other factors than availability of resources must come into play. It could relate to different beliefs of the medical community on the value of a given therapy in different countries. However, the focus on matched family donor transplant for non malignant disorders and chronic leukemia in lower income countries is suggestive for prioritization in a cost effectiveness approach. HSCT might be less expensive and equally effective as lifelong treatment with supportive care or expensive drugs in selected patients. There is no need for intensive high cost pre-treatment as is the case for patients with acute leukemia and, the search for a matched family donor requires minimal resources (17) (18) (19) (20) (21) .
Economic aspects of HSCT with its patient centered approach have traditionally concentrated on costs of the individual procedure for an individual patient. (17, (22) (23) (24) . Studies on macroeconomic aspects or on cost effectiveness in individual countries have gained broader acceptance only recently (11, 21, 22, and 25) . They were triggered in part by some rapid changes in use of HSCT, such as for breast cancer or chronic myeloid leukemia (18, 26) and by the raising awareness of the disturbing gap between unlimited requests and limited resources in any health care system (27, 28) . Availability of resources, governmental support and access to therapy were identified as factors associated with use; availability of resources, evidence, external regulations and positive or negative expectations of transplant physicians as factors associated with diffusion (11, 25) . These previous findings and the observations in this report syndromes or hemoglobinopathies are highly present in some and absent in other countries (31, 32) . Evidently, a few teams known to have performed HSCT did choose not to report (13) . Data reporting is mandatory by law in some, limited to allogeneic HSCT or even absent in other countries. The discrepancy between performed and reported HSCT might be higher for autologous than for allogeneic HSCT (9, 14-16). There is, however, no indication for a systematic bias and more recent data from the European survey are consistent with a widening gap (13).
The report gives no information on outcome. This requires additional time and another framework. Outcome is influenced by many factors, including the disease, the pre-treatment, patient and donor characteristics, transplant techniques, the transplant team, its quality management system or the income of the respective country (3, 5, (33) (34) (35) (36) . Combined analyses on use and outcome are needed to ascertain that those patients with the highest need and the best likelihood to profit from a transplant procedure are selected within a given country.
Transplant organizations and competent authorities worldwide are currently challenged to implement the WHO guiding principles. The present data provide a platform to begin with. They indicate that one size will not fit all. Regulatory aspects and recommendations on therapy should not only be transparent and consistent but as well be targeted according to the specific cost effectiveness considerations and needs in the individual countries (36, 37). 
Definitions
Transplant rates
Transplant rates were computed as the number of patients treated with a first HSCT per 10 million inhabitants (2) . Patients with a re-transplant or a second or third HSCT were not included. Transplant rates were computed by donor type, irrespective of stem cell source.
This did relate to cord blood transplants as well. There was no adjustment for patients who crossed borders and received their HSCT in a foreign country.
Population data and data on Gross National Income/capita (GNI/cap), Health Care 
World Health Organization regional offices areas
The allocation of individual countries to a region followed the WHO regional offices classification (www.who.int/about/regions/en/) and the previously reported restriction to four regions Turkey and Israel; Figure 1 ).
Statistical analysis
The association of macroeconomic factors with HSCT rates and the changes from 2006 to 2008 were estimated by single and multiple linear regression analyses using the least squares method. The significance of relationships was measured using τ statistics; a level of 5% was considered significant. The goodness of fit was calculated using the coefficient of determination (R 2 ), the square of the Pearson's correlation coefficient. For single and multiple regression analyses, the dependent variables were transformed to be closer to an underlying linear model. For the multiple regression analyses, all factors were assessed for their multicollinearity.
The t test was used to evaluate significant differences between the WHO regions. All statistical analyses were performed with EViews version 5.1 (Quantitative Micro Software, Irvine, California).
